Tissue transglutaminase (TG2) plays a central role in fibrosis, by recruiting TGF-β, disturbing extracellular matrix protein homeostasis and supporting fibroblast proliferation. Zedira scientists developed a new class of tissue transglutaminase inhibitors: reversible mode-of-inhibition, potent and selective. The novel compounds were optimized for in vivo oral bioavailability and favourable pharmacokinetic profiles. We refer to the respective press release.
Proprietary drug candidates are therefore available to target dysregulated active TG2 in fibrotic disorders, of the lung, kidney, and liver.
In July 2022 Dr. Falk Pharma and Zedira announced the start of the phase 2a proof of concept study of ZED1227 for the treatment of non-alcoholic fatty liver disease (NAFLD) (ress release).
Zedira offers partnerships for clinical development of these drug candidates.
Moreover, Zedira is planning to expand its global leadership position in the transglutaminase field by investing into follow-up drug discovery projects.